17α-羟孕酮己酸酯在单胎妊娠中的药代动力学及母体体型指标的影响
该前瞻性开放标签纵向群体药代动力学研究纳入56例16-36周单胎妊娠孕妇,每周肌注17α-羟孕酮己酸酯250 mg预防复发性自发性早产,共采集114份血浆样本。群体药代动力学分析显示,去脂体重最能解释个体间变异,去脂体重增加使清除率显著升高;模拟表明BMI>30 kg/m²孕妇固定剂量下血药浓度明显低于BMI<30者,按去脂体重调整剂量可使两组暴露几乎一致。
要点
- 去脂体重是影响17α-羟孕酮己酸酯清除率的最佳体型指标。
- BMI>30 kg/m²孕妇按固定250 mg肌注时血药浓度明显低于BMI<30者。
- 按去脂体重调整剂量可使不同体型孕妇获得几乎相同的血药浓度。
核心结论
- 群体药代动力学分析表明17α-羟孕酮己酸酯清除率随去脂体重增加而显著升高。
- BMI>30 kg/m²孕妇可能需要按母体去脂体重调整的更高剂量以达到与BMI<30者等效的血浆浓度。
- 按去脂体重调整17α-羟孕酮己酸酯剂量可使不同体型孕妇获得等效的系统暴露。
研究设计与样本
- 前瞻性、开放标签、纵向设计的群体药代动力学研究。
- 纳入56例18-44岁、BMI 14.5-54.6 kg/m²、孕16-36周单胎妊娠孕妇。
- 每周肌注17α-羟孕酮己酸酯250 mg用于预防复发性自发性早产,共采集114份血浆样本。
- 采用混合效应模型估计药代动力学参数及显著临床协变量。
主要发现
- 一室模型加一级吸收可满意描述17α-羟孕酮己酸酯的药代动力学。
- 去脂体重较其他体型指标更能解释个体间变异。
- 年龄、种族和孕周不影响17α-羟孕酮己酸酯的药代动力学。
- 模拟显示固定250 mg肌注时BMI>30 kg/m²孕妇血浆浓度明显低于BMI<30 kg/m²孕妇。
- 按总体重调整剂量使BMI>30 kg/m²孕妇浓度明显高于低BMI组,按去脂体重调整则两组几乎一致。
关键数值与推荐
- 研究给药方案为17α-羟孕酮己酸酯250 mg肌内注射、每周一次。
- 纳入孕妇BMI范围为14.5-54.6 kg/m²,年龄18-44岁,孕16-36周。
- 模型比较了去脂体重、总体重、体质指数和体表面积四种体型指标。
- 模拟对比了BMI>30 kg/m²与BMI<30 kg/m²两组在固定剂量及调整剂量下的血浆浓度。
临床怎么用
- 对BMI>30 kg/m²的单胎妊娠孕妇使用17α-羟孕酮己酸酯预防复发性早产时,需关注固定250 mg剂量下暴露可能偏低。
- 按去脂体重调整17α-羟孕酮己酸酯剂量可能使不同体型孕妇获得等效系统暴露。
- 年龄、种族和孕周无需作为17α-羟孕酮己酸酯剂量调整的依据。
局限性
- 样本量56例、血浆样本114份,样本量有限。
- 研究为开放标签设计,未设盲。
- 原文未报告临床结局数据,药代动力学模拟结果需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Reducing spontaneous preterm deliveries is a worldwide public health priority. Although many interventions have been studied, 1 of the most effective treatments to decrease recurrent preterm birth is the use of weekly 17 alpha hydroxy progesterone caproate. Previous studies on the influence of excessive adipose tissue and obesity on the use of 17 alpha hydroxyprogesterone caproate for the prevention of recurrent spontaneous preterm deliveries have shown conflicting findings. OBJECTIVE: To estimate the pharmacokinetics of weekly17 alpha hydroxyprogesterone caproate in singleton and to evaluate the effect of maternal body size on the pharmacokinetics parameters. STUDY DESIGN: A prospective, open-label, longitudinal design was implemented for this population pharmacokinetic study. Plasma samples and clinical variables were collected in pregnant women between 16 and 36 weeks' gestational age, carrying a singleton pregnancy and receiving 17 alpha hydroxyprogesterone caproate, 250 mg intramuscularly weekly for the prevention of recurrent spontaneous preterm birth. Pharmacokinetics parameters and significant clinical covariates were estimated using mixed effect modeling. Four body size indicators were used in the model to predict pharmacokinetics parameters: lean body weight, total body weight, body mass index, and body surface area. RESULTS: A total of 56 pregnant women, aged 18-44 years with body mass index of 14.5-54.6 kg/m2, provided 114 17 alpha hydroxyprogesterone caproate plasma samples concentration for analysis. A 1-compartment model with first-order absorption satisfactorily described 17 alpha hydroxyprogesterone caproate pharmacokinetics. Compared to other body size indicators, lean body weight best explained intersubject variability. Age, race, and gestational age did not influence 17 alpha hydroxyprogesterone caproate pharmacokinetics. Lean body weight was the best descriptor for the influence of body size on 17 alpha hydroxyprogesterone caproate apparent clearance. Simulations showed that administration of a standard fixed dose of 250 mg intramuscularly produced substantially lower 17 alpha hydroxyprogesterone caproate plasma concentrations in pregnant women with body mass index >30 kg/m2 compared to those with body mass index <30 kg/m2. Conversely, adjustment of the standard dose for differences in total body weight among women resulted in markedly higher 17 alpha hydroxyprogesterone caproate concentrations in women with body mass index >30 kg/m2 compared to women with lower body mass index. Administration of doses adjusted for lean body weight produced nearly identical 117 alpha hydroxyprogesterone caproate plasma concentrations in both the low- and high-body mass index groups. CONCLUSION: Population pharmacokinetics analysis indicates the clearance significantly increases with increasing lean body mass. Higher 17 alpha hydroxyprogesterone caproate doses, adjusted by maternal lean body mass, may be required in patients with a body mass index >30 to achieve equivalent plasma concentrations in pregnant women with a body mass index <30. Adjustment of 17 alpha hydroxyprogesterone caproate doses for lean body weight produces equivalent systemic 17 alpha hydroxyprogesterone caproate exposure in pregnant women regardless of body size.
引用
- Della Torre M, Enakpene C, Ravangard S, et al. Pharmacokinetics of 17 alpha hydroxyprogesterone caproate in singleton pregnancy and its influence of maternal body size measures. Am J Obstet Gynecol MFM. 2019. PMID: 33345841. doi:10.1016/j.ajogmf.2019.100051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。